Fasenra onto PBS

Pharmacy Daily - - News -

AS­TRAZENECA has an­nounced the Phar­ma­ceu­ti­cal Ben­e­fits Scheme list­ing of its Fasenra (ben­ral­izumab) for pa­tients with se­vere eosiniphilic asthma who meet spe­cific cri­te­ria.

Fasenra is a mon­o­clonal an­ti­body that works with the body’s im­mune sys­tem to specif­i­cally tar­get eosinophils, a par­tic­u­lar type of white blood cell which are present in half of Aus­tralians with un­con­trolled se­vere asthma.

It is ad­min­is­tered by a health­care pro­fes­sional as a sub­cu­ta­neous in­jec­tion ev­ery eight weeks, fol­low­ing ini­ti­a­tion with three four­weekly doses.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.